Regard of functional pharmacogenetic polymorphisms may further the success of pain therapy by adopting individualized approaches. The l-opioid receptor gene (OPRM1) 118A>G polymorphism is a promising candidate for both opioid effects and pain because of both biological reasonability and apparent experimental and clinical evidence. We analyzed its importance for pain therapy using a meta-analytic approach to studies relating it to opioid pain therapy. Data from suitable studies selected from hits of a PubMed search for ''OPRM1" were independently extracted by two authors. The meta-analysis included phenotypes by OPRM1 genotype (opioid dosing, pain, and side effects), publication year, diagnostic status, proportion of male study participants, and whether genotype frequencies agreed with Hardy-Weinberg equilibrium. We found no consistent association between OPRM1 118A>G genotypes and most of the phenotypes in a heterogeneous set of eight clinical studies. Only weak evidence of an association with less nausea (effect size, Cohen's d = À0.21, p = 0.037) and of increased opioid dosage requirements (d = 0.56, p = 0.018) in homozygous carriers of the G allele was obtained. This indicates that despite initially promising results, available evidence of the clinical relevance of the OPRM1 118A>G polymorphism does not withhold a meta-analysis. This discourages basing personalized therapeutic concepts of pain therapy on OPRM1 118A>G genotyping at the present state of evidence. Ó
a b s t r a c t
Regard of functional pharmacogenetic polymorphisms may further the success of pain therapy by adopting individualized approaches. The l-opioid receptor gene (OPRM1) 118A>G polymorphism is a promising candidate for both opioid effects and pain because of both biological reasonability and apparent experimental and clinical evidence. We analyzed its importance for pain therapy using a meta-analytic approach to studies relating it to opioid pain therapy. Data from suitable studies selected from hits of a PubMed search for ''OPRM1" were independently extracted by two authors. The meta-analysis included phenotypes by OPRM1 genotype (opioid dosing, pain, and side effects), publication year, diagnostic status, proportion of male study participants, and whether genotype frequencies agreed with Hardy-Weinberg equilibrium. We found no consistent association between OPRM1 118A>G genotypes and most of the phenotypes in a heterogeneous set of eight clinical studies. Only weak evidence of an association with less nausea (effect size, Cohen's d = À0.21, p = 0.037) and of increased opioid dosage requirements (d = 0.56, p = 0.018) in homozygous carriers of the G allele was obtained. This indicates that despite initially promising results, available evidence of the clinical relevance of the OPRM1 118A>G polymorphism does not withhold a meta-analysis. This discourages basing personalized therapeutic concepts of pain therapy on OPRM1 118A>G genotyping at the present state of evidence.
Ó 2009 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
Introduction
The , inclusion of the 118A>G variant into personalized pain therapeutic concepts is increasingly contemplated. We therefore assessed whether current evidence about the clinical relevance of the OPRM1 118A>G SNP for pain therapy withholds a meta-analytic evaluation.
Methods

Search strategy and paper inclusion criteria
A PubMed database search (http://www.ncbi.nlm.nih.gov/sites/ entrez) for ''OPRM1" on February 15, 2009 resulted in 174 hits. Papers were excluded for the following reasons: (i) no human data or only in vitro assessment, (ii) the human 118A>G variant was not included or no separate data were reported for this variant, which excluded haplotypes without reports of SNP effects, (iii) no clinical data from patients were reported, which excluded preclinical studies employing experimental models in healthy volunteers, (iv) no reference was made to pain or analgesia, which excluded the reports focusing exclusively on addiction, (v) opioid effects were not addressed, which excluded observations of genetic effects but not pharmacogenetic effects, (vi) overlap of reported data between
